Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck And Cipla Bury Differences To Co-market Raltegravir In India

This article was originally published in PharmAsia News

Executive Summary

Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.


Related Content

ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts